A symposium presented at the American Association for Cancer Research Annual Meeting 2016 offers updated results on the ongoing phase 1b clinical trial of anti-PDL1 immunotherapy atezolizumab in advanced stage colorectal ...
Apr 18, 2016
0
15
Tumor shrinkage is not the only measure of a successful anti-cancer therapy. A University of Colorado Cancer Center article published in the journal Frontiers in Oncology describes a promising alternative: metabolic imaging. ...
Aug 9, 2016
0
4
A team of researchers at Baylor College of Medicine, Texas Children's Hospital, the Hospital for Sick Children in Toronto and collaborating institutions has identified and located a population of stem-like cells that initiates ...
Jul 9, 2024
0
58
New results from a clinical trial conducted in Shanghai, China, indicate that adding cetuximab (Erbitux) to standard chemotherapy enables some patients with otherwise inoperable liver metastases due to colorectal cancer have ...
Apr 8, 2013
0
0
A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...
May 17, 2013
0
0
(HealthDay) -- The potent, selective vascular endothelial growth factor receptor-1, -2, and -3 inhibitor, tivozanib, demonstrates antitumor activity and is well tolerated in patients with advanced/metastatic renal cell carcinoma ...
Apr 10, 2012
0
0
Shares of drugmaker Amgen Inc. are rising on news its innovative melanoma drug, which uses a virus as a Trojan horse to infiltrate and destroy tumors, shrank far more tumors than a standard treatment in a late-stage test.
Mar 20, 2013
0
0
Treatment with the investigational pan-AKT inhibitor AZD5363 led to tumor regression in patients with a variety of types of solid tumors positive for the AKT1 E17K genetic mutation, according to data from a phase I clinical ...
Nov 9, 2015
0
3
A novel chemotherapeutic agent, the highly selective MEK1/2 inhibitor BAY 86-9766, may be a promising future treatment for pancreatic ductal adenocarcinoma (PDAC), according to preclinical results presented at the American ...
Jun 20, 2012
0
0
The investigational, oral drug BGJ398, which blocks the activity of a family of proteins called fibroblast growth factor receptors (FGFRs), showed promising anticancer activity in patients with various types of cancer driven ...
Apr 9, 2014
0
0
